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Use of methods for specifying the target
difference in randomised controlled trial sample
size calculations: Two surveys of trialists’ practice
Jonathan A Cooka,b, Jennifer M Hislopc, Doug G Altmanb, Andrew H Briggsd, Peter M Fayerse,f,
John D Norriea, Craig R Ramsaya, Ian M Harveyg, Luke D Valec; for the DELTA group
Background Central to the design of a randomised controlled trial (RCT) is a calcu-
lation of the number of participants needed. This is typically achieved by specifying
a target difference, which enables the trial to identify a difference of a particular
magnitude should one exist. Seven methods have been proposed for formally deter-
mining what the target difference should be. However, in practice, it may be driven
by convenience or some other informal basis. It is unclear how aware the trialist
community is of these formal methods or whether they are used.
Purpose To determine current practice regarding the specification of the target dif-
ference by surveying trialists.
Methods Two surveys were conducted: (1) Members of the Society for Clinical Trials
(SCT): participants were invited to complete an online survey through the society’s
email distribution list. Respondents were asked about their awareness, use of, and will-
ingness to recommend methods; (2) Leading UK- and Ireland-based trialists: the sur-
vey was sent to UK Clinical Research Collaboration registered Clinical Trials Units,
Medical Research Council UK Hubs for Trial Methodology Research, and the Research
Design Services of the National Institute for Health Research. This survey also included
questions about the most recent trial developed by the respondent’s group.
Results Survey 1: Of the 1182 members on the SCT membership email distribution
list, 180 responses were received (15%). Awareness of methods ranged from 69
(38%) for health economic methods to 162 (90%) for pilot study. Willingness to
recommend among those who had used a particular method ranged from 56%
for the opinion-seeking method to 89% for the review of evidence-base method.
Survey 2: Of the 61 surveys sent out, 34 (56%) responses were received. Awareness
of methods ranged from 33 (97%) for the review of evidence-base and pilot meth-
ods to 14 (41%) for the distribution method. The highest level of willingness to
recommend among users was for the anchor method (87%). Based upon the most
recent trial, the target difference was usually one viewed as important by a stake-
holder group, mostly also viewed as a realistic difference given the interventions
under evaluation, and sometimes one that led to an achievable sample size.
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Limitations The response rates achieved were relatively low despite the surveys
being short, well presented, and having utilised reminders.
Conclusion Substantial variations in practice exist with awareness, use, and willing-
ness to recommend methods varying substantially. The findings support the view
that sample size calculation is a more complex process than would appear to be the
case from trial reports and protocols. Guidance on approaches for sample size
estimation may increase both awareness and use of appropriate formal methods.
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Introduction
Central to the design of a randomised controlled
trial (RCT) is a calculation of the number of partici-
pants needed [1,2]. As part of this calculation, a tar-
get difference, the magnitude of a difference which
is desired to be detected, is typically specified to pro-
vide reassurance that the trial will be informative
and able to answer the research question posed with
required statistical precision and certainty. It is
important that an appropriate number of partici-
pants are sought as too large or small a study is argu-
able unethical, wasteful, and potentially misleading.
Despite its critical role, the specification of the target
difference has received little attention. A detailed sys-
tematic review and synthesis of the literature, which
is reported elsewhere [3], identified seven methods
for specifying a target difference (see Table 1). It is
unclear the extent to which trialists are aware of
these methods and whether they are used in practice
when designing clinical trials. Reports of trial results
and protocols will typically report the sample size cal-
culation and the values assumed therein [1]. The pro-
cess of how these values were determined (including
the target difference) typically lacks detail, particu-
larly in reports of trial results where there are space
restrictions. Arguably, it is those with practical experi-
ence of designing RCTs who are best placed to pro-
vide advice about the use of such methods in their
experience. Furthermore, there may be other meth-
ods or existing methods that are implemented in a
way that has not been captured from the systematic
review of the literature. To address this, we sought to
assess the usage of methods among leading clinical
trialists.
This was achieved using two related surveys: one
of the membership of the International Society for
Clinical Trials (SCT) [4] and one of the UK- and Ire-
land-based trialists [5–7]. The aim of the surveys
was to evaluate current practice among clinical tri-
alists, specifically, which methods respondents
were aware of, used, and would be willing to
recommend. While the two surveys were similar,
the second, to UK- and Ireland-based trialists, was
slightly more extensive (see below for details). This
work was part of the Difference ELicitation in
TriAls (DELTA) project: a study on target differ-
ences commissioned by the Medical Research
Council, UK (MRC)/National Institute for Health
Research (NIHR) Methodology Research Panel and
is reported in detail elsewhere [3].
Methodology of the surveys
Survey 1: SCT membership
Members of the SCT were surveyed (sent 24 August
2011) [4]. The survey asked generic questions about
the individual responding (position, affiliation, loca-
tion, and whether they are currently involved in the
design of RCTs), and about their group’s awareness
and usage of methods for determining the target dif-
ference, with the opportunity to suggest additional
methods provided (see online Appendix 1). A brief
summary of the seven previously identified meth-
ods was provided in the online form. Additionally,
the respondents were asked whether they would be
willing to recommend the use of any of the meth-
ods. Finally, an opportunity to comment on the
issue was provided. Members received an email invi-
tation sent via the society’s email distribution list,
inviting them to complete the online survey. The
invitation included a brief introduction to this
issue and the aim of the survey. The online survey
was setup bespoke for this purpose by the Univer-
sity of Aberdeen’s Health Services Research Unit
(HSRU) Programming team. Once potential partici-
pants received the email, they were able to access
the survey by clicking on the URL hyperlink pro-
vided. A generic reminder was sent to the entire
study sample 1 week after the initial email invita-
tion (it was not possible to tailor reminders to
individuals).
Survey 2: UK- and Ireland-based trialists
The sample for the survey of UK- and Ireland-based
trialists included three groupings who contribute to
trial design: UK Clinical Research Collaboration
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(UKCRC) registered Clinical Trials Units (CTUs) [6],
Regional NIHR Research Design Service (RDS) offices
in England [7], and the MRC UK Hubs for Trial
Methodology Research [5] (as of 24 August 2011).
One individual (typically the Director) from the
CTUs, MRC Hubs, and RDS offices was invited to
complete the survey (sent 24 August 2013). Where
the same individual held a position with more than
one entity, only one survey was sent and a response
on behalf of the relevant groups requested. They
were requested to forward the survey to the appro-
priate member of their group if they were not per-
sonally able to complete it.
In addition to the information collected in the
SCT survey, this survey (see online Appendix 2)
requested information about the most recent trial
developed from the UK- and Ireland-based trialists
sample. These details included the underlying basis
adopted for the target difference (e.g., realistic differ-
ence or important difference) and any methods for
determining the target difference used. Additionally,
they were asked whether there is anything that
would aid them in the design of RCTs and whether
they would be happy to be contacted for further
details. The initial request was personalised and sent
by post and included an invitation letter, paper ver-
sion of the survey, and description of the methods
available for determining the difference. A paper
reminder was sent 2 weeks from the initial notifica-
tion of the survey. Following this, an additional
(final) email reminder was sent after another week
with an electronic invitation, version of the survey,
and description of the methods.
Ethical review
The surveys were approved by the University of
Aberdeen’s College of Life Sciences and Medicine
Ethics Review Board (CERB/2011/6/657). This pro-
ject abided by the MRC’s guidance on Good
Research Practice and conformed to the University
of Aberdeen’s Research Governance Guidelines. We
piloted the survey invitations and formats with
members of the project team and local researchers.
The responses to the online survey and submitted
Table 1. Methods for specifying an important and/or realistic difference
Methods for specifying an important difference
 Anchor. The outcome of interest can be ‘anchored’ by using either a patient’s or health professional’s judgement to define an
important difference. This may be achieved by comparing a patient’s health before and after treatment and then linking this change
to patients who showed improvement/deterioration using a more familiar outcome (for which either patients or health professionals
more readily agree on what amount of change constitutes an important difference). Alternatively, a contrast between patients can
be made to determine a meaningful difference.
 Distribution. Approaches that determine a value based upon distributional variation. A common approach is to use a value that is
larger than the inherent imprecision in the measurement and therefore likely to represent a minimal level for a noticeable difference.
 Health economic. Approaches that use principles of economic evaluation. These typically involve including both resource cost and
health outcomes and defining a threshold value for the cost of a unit of health effect that a decision-maker is willing to pay, to
estimate the overall net-benefit of treatment. The net-benefit can be analysed in a standard frequentist framework or take the form
of a (typically Bayesian) decision-theoretic value of information analysis.
 Standardised effect size. The magnitude of the effect on a standardised scale defines the value of the difference. For a continuous
outcome, the standardised difference (most commonly expressed as Cohen’s d ‘effect size’) can be used. Cohen’s cut-offs of 0.2, 0.5,
and 0.8 for small, medium, and large effects, respectively, are often used. Thus, a ‘medium’ effect corresponds simply to a change in
the outcome of 0.5 standard deviations. Binary or survival (time-to-event) outcome metrics (e.g., an odds, risk, or hazard ratio) can
be utilised in a similar manner, although no widely recognised cut-offs exist. Cohen’s cut-offs approximate to odds ratios of 1.44,
2.48, and 4.27, respectively. Corresponding risk ratio values vary accordingly to the control group event proportion.
Methods for specifying a realistic difference
 Pilot study. A pilot (or preliminary) study may be carried out where there is little evidence, or even experience, to guide expectations
and determine an appropriate target difference for the trial. In a similar manner, a phase II study could be used to inform a phase III
study.
Methods for specifying an important and/or a realistic difference
 Opinion-seeking. The target difference can be based on opinions elicited from health professionals, patients, or others. Possible
approaches include forming a panel of experts, surveying the membership of a professional or patient body or interviewing
individuals. This elicitation process can be explicitly framed within a trial context.
 Review of evidence base. The target difference can be derived using current evidence on the research question. Ideally, this would be
from a systematic review or meta-analysis of RCTs. In the absence of randomised evidence, evidence from observational studies
could be used in a similar manner. An alternative approach is to undertake a review of studies in which an important difference was
determined.
RCT: randomised controlled trial.
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survey data are stored within a secure database on a
secure server.
Data analysis
The surveys were analysed separately. The response
rate was defined as the respective number of
responding participants divided by the number of
potential participants in the population. The statis-
tical analysis was descriptive. Responses were sum-
marised quantitatively or narratively as appropriate.
Results
Survey 1: SCT membership
Of the 1182 members on the SCT membership (519
of whom described themselves as statistician, epide-
miologist, or principal investigator) email distribu-
tion list, 180 responses were received (15%).
Respondent characteristics are given in Table 2. A
total of 13 countries were represented, although
over 75% were from North America (127 and 15
respondents from the United States and Canada,
respectively). In all, 18 respondents were based in
the United Kingdom. The vast majority of respon-
dents were statisticians/epidemiologists, with only
13 respondents being health professionals. The
affiliation of the majority was an academic institu-
tion with similar numbers from a contract research
organisation, private industry, and a regulatory
authority. Of the 180 respondents, 162 (90%) stated
they were presently involved in trial design.
The responses regarding awareness, usage, and
willingness to recommend methods are given in
Table 3. Awareness of methods ranged from 69
(38%) for health economic methods to 162 (90%)
for pilot study. No additional method was reported.
As expected, usage was lower than awareness and
ranged from 16 (9%) for the health economic to 133
(74%) for pilot study. The use of treatment selection
methods and continual reassessment method and
other adaptive models was highlighted, although
these typically are based upon an arbitrary, though
pre-specified, sample size [8].
The highest level of willingness to recommend
was for review of evidence base (73%) and the
Table 2. Respondent characteristics (survey 1, N = 180)
Characteristic % of respondents (n)
Locationa
United States 71 (127)
United Kingdom 10 (18)
Canada 8 (15)
Other European country 6 (10)
Japan 2 (3)
Australia 2 (3)
African country 1 (2)
China 1 (1)
Profession
Health professional 7 (13)
Statisticians/epidemiologists 85 (153)
Other scientist (e.g., ethicist or
behavioural scientist)
1 (2)
Trial staff 4 (8)
Other 2 (4)
Institutiona
Academic institution 58 (103)
Contract research organisation 13 (23)
Governmental agency 9 (17)
Health-care provider 3 (6)
Private industry 13 (24)
Other 3 (6)
Currently involved in trial design
Yes 90 (162)
aBased upon N = 179 as one respondent did not complete.
Table 3. Responses regarding awareness, usage, and willingness to recommend methodsa (survey 1, N = 180)
Method Aware of Used Recommend Recommend if used
% (n) % (n) % (n) % (n)
Anchor 43 (77) 33 (59) 30 (54) 71 (42)
Distribution 58 (104) 40 (72) 33 (60) 68 (49)
Health economic 38 (69) 9 (16) 16 (28) 69 (11)
Opinion-seeking 59 (106) 40 (72) 32 (58) 56 (40)
Pilot study 90 (162) 74 (133) 65 (117) 77 (103)
Review of evidence base 87 (156) 73 (132) 73 (132) 89 (118)
Standardised effect size 77 (138) 58 (104) 41 (73) 63 (65)
Other 0 (0) 0 (0) 0 (0) NA
None 2 (3) 3 (6) 3 (6) NA
NA: not applicable.
aRespondents were invited to select all that apply.
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lowest was health economic (16%). Willingness to
recommend was lower than awareness and usage for
all methods except for the health economic method
where the number willing to recommend this
method although less than the number aware of it
was more than usage (16% vs. 9%, respectively).
Willingness to recommend among only those who
had used a particular method was substantially
higher than across all respondents ranging from
56% for opinion-seeking method to 89% for review
of evidence-base method for specified methods.
Survey 2: UK- and Ireland-based trialists
Information on the groups represented is given in
Table 4. Of the 61 surveys sent out, 34 (56%)
responses were received representing: 25 (52%), 5
(63%), and 8 (80%) of CTUs, methodology trial
Hubs, and RDS offices, respectively (some having
more than one affiliation). Respondents were predo-
minately directors of one of these institutions (26,
76%), with the remainder being a statistician (3,
9%) or others (5, 15%). The vast majority stated
their group dealt with both pharmacological and
non-pharmacological trials (29, 88%) and (32, 97%),
respectively. With regard to RCT phases, the group’s
trial portfolio contained 24 (73%), 31 (94%), and 19
(58%) for phases II–IV, respectively. One (3%)
reported also undertaking a phase I study. All clini-
cal areas under the NIHR UK portfolio categorisation
were represented with frequencies ranging from 4
(12%) for ear to 24 (73%) for primary care–related
research.
The responses regarding awareness, usage, and
willingness to recommend methods are given in
Table 5. Awareness of methods ranged from 33
(97%) for the opinion-seeking and pilot study meth-
ods, to only 14 (41%) for distribution method. No
other methods were suggested, and all stated that
they had used at least one of the methods. The use
of methods was substantially less than awareness
except for the pilot study, review of evidence base,
and standardised effect size methods. All respon-
dents were aware of at least one of the different for-
mal methods for determining the target difference.
Almost all had used at least two methods (94%).
One respondent stated their group had not used any
of the methods as they had only recently formed.
The highest level of willingness to recommend was
for review of evidence base (76%) followed by stan-
dardised effect size (65%). The vast majority (88%)
recommended more than one method. Two respon-
dents (6%) stated that they would not recommend
any method. The use of the anchor and review of
evidence base in combination was suggested by one
respondent. The difficulty in differentiating between
some of the methods without full definitions was
noted by another respondent.
Data on the most recent trial the respondent’s
group had been involved with is given in Tables 5
and 6. Based upon the most recent trial, all bar three
groups used a formal method. In all, 21 (62%) stated
using more than one formal method. Two respon-
dents reported that their group had used alternative
Table 4. Respondent characteristics (survey 2, N = 34)
Characteristics % of respondents (n)
Representing
CTU 52% of CTUs (25)
Hub 63% of Hubs (5)
RDS 80% of RDS offices (8)
Position
Director 76 (26)
Statistician 9 (3)
Other 15 (5)
Intervention types
in trial portfolioa,b
Pharmacological 88 (29)
Non-pharmacological 97 (32)
Phase of trial in portfolioa,b
I 3 (1)
II 73 (24)
III 94 (31)
IV 58 (19)
Clinical area in trial portfolioa,b
Blood 15 (5)
Cancer 67 (22)
Cardiovascular 55 (18)
Dementias and neurodegenerative
diseases
45 (15)
Diabetes 48 (16)
Ear 12 (4)
Eye 18 (6)
Genetics and congenital disease 18 (6)
Infection 36 (12)
Inflammatory and immune 21 (7)
Injuries and emergencies 30 (10)
Medication for children 42 (14)
Mental health 58 (19)
Metabolic and endocrine 24 (8)
Musculoskeletal 52 (17)
Neurological 33 (11)
Oral and gastrointestinal 42 (14)
Primary care 73 (24)
Renal 39 (13)
Reproductive heath 42 (14)
Respiratory 42 (14)
Skin 30 (10)
Stroke 52 (17)
CTU: Clinical Trials Unit; RDS: Research Design Service.
aRespondents were invited to select all that apply.
bBased upon N = 33 as one CTU had only recently started.
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informal methods: reverse engineering the study
sample size to ensure the research cost fell ‘within
funding’ range and basing it upon the lead clinical
applicant’s opinion although this was not formally
elicited, respectively. The most common type of pri-
mary outcome in the most recent trial conducted by
the respondent’s group was a clinical function mea-
sure (33%) followed by mortality outcome (27%).
Disease-specific (21%) and generic (12%) quality-of-
life measures were also represented in multiple stu-
dies. A non-quality of life patient reported outcome
and a health economic measure were each reported
twice as being used as the primary outcome. Other
outcome types were non-mortality time-to-event
(6%), cardiovascular events (6%), weight-related out-
comes (6%), length of stay, and violent events. In
one case, there was no primary outcome and 11
(34%) had more than one primary outcome. There
was no clear link between outcome type and meth-
ods used with a spread of methods used for the more
common outcome types (quality of life, mortality,
and clinical outcome measures).
The vast majority stated that the target difference
was one that was viewed as important by a stake-
holder group (91%). Just over half the respondents
(61%) stated the basis for determining the target dif-
ference was to achieve a realistic difference given
the interventions under evaluation. In all, 11
respondents (33%) stated that it was a difference
that gave an achievable sample size. One considered
what difference would be worthwhile detecting
given the cost of the intervention and the other
Table 5. Responses regarding awareness, use, and willingness to recommend methodsa (survey 2, N = 34)
Method Aware of Used Recommend Recommend if used Most recent trialb
% (n) % (n) % (n) % (n) % (n)
Anchor 65 (22) 44 (15) 47 (16) 87 (13) 18 (6)
Distribution 41 (14) 24 (8) 26 (9) 38 (3) 3 (1)
Health economic 62 (21) 24 (8) 32 (11) 63 (5) 3 (1)
Opinion-seeking 88 (30) 53 (18) 53 (18) 78 (14) 27 (9)
Pilot study 97 (33) 88 (30) 59 (20) 67 (20) 24 (8)
Review of evidence base 97 (33) 94 (32) 76 (26) 78 (25) 52 (17)
Standardised effect size 88 (30) 82 (28) 65 (22) 79 (22) 42 (14)
Other 0 (0) 0 (0) 0 (0) NA 0 (0)
None 0 (0) 3 (1) 6 (2) NA 9 (3)
NA: not applicable; CTU: Clinical Trials Unit.
aRespondents were invited to select all that apply.
bBased upon N = 33 as one CTU had only recently started.
Table 6. Most recent trial (survey 2, N = 33a)
Most recent trial % of respondents (n)
Primary outcomeb
Generic quality of life (e.g., EQ-5D) 12 (4)
Disease-specific quality of life (e.g., Oxford Knee Score) 21 (7)
Other patient reported outcome (non-quality-of-life measure) 6 (2)
Mortality 27 (9)
Clinical functional measure (e.g., forced expiratory volume (FEV)) 33 (11)
Economic outcome (e.g., incremental cost per QALY) 6 (2)
Other 24 (8)
There was no primary outcome 3 (1)
What was the underlying principle(s) adopted in determining the difference?b
A realistic difference given the interventions under evaluation 61 (20)
A difference which would led to an achievable sample size 33 (11)
A difference that would be viewed as important by a relevant stakeholder group (e.g., clinicians) 91 (30)
Other 6 (2)
CTU: Clinical Trials Unit; QALY: quality-adjusted life year.
aBased upon N = 33 as one CTU had only recently started.
bRespondents were invited to select all that apply.
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considered what magnitude of a target difference
(and hence size and cost of project) would likely to
be funded. In all, 10 (30%), 7 (21%), and 2 respon-
dents (6%), respectively, reported using two, three,
and four bases of consideration when determining
the target difference. Of the 19 respondents with
two or more bases, 16 stated they sought both a rea-
listic and an important differences. Two respon-
dents used an addition basis for determining the
target difference in combination with all three pre-
specified approaches (a difference that was realistic,
important to stakeholder, and achievable): the cost
of the intervention and the ‘likelihood of securing
funding’.
Discussion
The two surveys of current practice provided insight
into the current practice among clinical trialists
regarding specification of the target difference. To
our knowledge, this has not been done before.
Responses suggest that use of formal methods is
greater than would appear the case from trial reports
[1,9,10] or at least, the use of methods is higher for
the type of RCTs that the second survey represents.
The two surveys represented different stakeholders:
an international society of people involved in clinical
trials and leading UK- and Ireland-based trialists. Var-
iations in awareness, use, and willingness to recom-
mend between methods were substantial between
respondents to the two surveys. There was some dif-
ference in the responses between the two groups
which might be expected given the more heteroge-
neous composition of the SCT sample. Nevertheless,
the findings support the view that sample size calcu-
lation is a more complex process than would appear
to be the case from trial reports and protocols.
In both surveys, the awareness of formal methods
was high for most methods although for some,
notably the anchor, distribution, and health eco-
nomic methods, it was substantially lower than for
others. Awareness of the opinion-seeking method
was lower in the SCT sample than among the UK-
and Ireland-based trialists. This may reflect a greater
focus among the SCT membership upon pharmaco-
logical trials conducted for regulatory approval
where phase II trial results typically informs the
phase III trial and the phase II sample size is influ-
enced by convention/regulatory body expectations.
The pattern of use of methods was broadly the same
as awareness.
With regard to recommendations for use by
researchers, the review of the evidence-base method
consistently had the highest level of recommenda-
tion across the two surveys. In both surveys, the use
of an informal approach such as ‘reverse engineering’
to suit expected recruitment and associated research
cost was mentioned. Slightly more respondents were
willing to recommend the health economic method
than had actually used it (although in both cases, the
number recommending was low compared with
most of the other methods), perhaps reflecting the
intuitive appeal of this approach and that cost con-
siderations influence decisions about study design
even when not explicitly stated. The lack of use of
the health economic approaches may relate to its
more recent development, lack of expertise, and
resources necessary to conduct this approach.
Exploration of the basis for calculating the target
difference was further explored in more depth in
the second survey by referring to the last trial their
group had been involved in. Details about the most
recent trial conducted by respondents reflected a
wide variety of outcome types, for which all of the
methods were used to varying degrees. While the
vast majority stated that the basis for the target dif-
ference was a difference viewed as important by a
stakeholder group, most also used another basis and
two used four separate bases (difference viewed as
important to stakeholder, realistic, achievable, and
either the cost of the intervention or consideration
of funding) for determining the target difference.
Furthermore, the majority of respondents stated
they had used more than one method in determin-
ing the sample size calculation. Such complexity of
considerations, in our experience, is rarely reported
in the sample size section either in the trial report or
the protocol. This view is supported by a review of
sample size calculations in RCTs [1]. Clearer and
more explicit reporting of the basis for determining
the target difference, including any formal methods
used, is needed.
Funders of RCTs naturally consider the associated
research cost of the study and the feasibility of the
proposal, and this was recognised by respondents to
both surveys. The desirable precision may be prohi-
bitively high or impractical to achieve. For respon-
dents, the dilemma as to how best to balance the
cost of a trial against the need for a large (and by
extension an expensive) trial may be needed to
answer the research question. This tension led more
than one respondent to query how often the target
difference is honestly chosen as opposed to being
picked to make the sample size ‘affordable’. Simi-
larly, the need to choose a sample size that would
allow a realistic recruitment rate was also raised.
How cost and feasibility should be taken into
account may be unclear to applicants and lead to a
reluctance to be explicit about the practical consid-
erations. In principle, these are the sort of considera-
tions that the economic value of information
methods appears capable of capturing while ensur-
ing that the cost of data collection is less than the
value generated by the RCT. Furthermore, such an
approach could be tailored to a funder’s perspective
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and considerations. Nevertheless, while there is
some awareness of these techniques, there is little
evidence of their widespread use in practice.
The need for guidance via a central resource to
clarify what is clinically important for common out-
comes (one specifically regarding the patient per-
spective) and guidance on what methods are
appropriate and in what situation is clear from the
survey results. Such guidance, as some survey
respondents themselves note, would need to recog-
nise trial specifics (e.g., the phase of the trial) and
dependent upon the type of outcome, the resources
(time, expertise, etc.) available to implement meth-
ods, current knowledge of the clinical area, and also
the proposed trial analysis (e.g., Bayesian [11] or
update of a meta-analysis) [12].
The response rates achieved were relatively low
despite the surveys being short and well presented
and having utilised reminders. However, we view it
as unlikely that non-response has led to unrepresen-
tative findings and suspect the low response rate
reflects the difficulty of achieving high rates in cer-
tain population groups [13] along with the lower
response rate from email distribution lists, as was
used in the SCT survey. A further factor may be the
nature of the survey; it focused on RCT methodol-
ogy, which made determining who should be invited
to respond, and perhaps also completion, less than
straightforward and required consideration of a port-
folio of research projects. One respondent noted the
difficulty in differentiating between some of the
methods despite a brief description being provided.
There may also have been some overlap in respon-
dents between the two surveys. Nevertheless, the
surveys provided insightful information about the
practice and views of trialists from a range of back-
grounds regarding determining the target difference.
The second survey included MRC Hubs for Trial
Methodology and the 10 regional centres of the
NIHR RDS in addition to CTUs. This reflects the var-
ied way in which the design of RCTs is dealt with in
the United Kingdom and Ireland. For example, in
Scotland, CTUs typically design trials ‘in-house’ or
have a very close affinity with a research group
within their host institution. However, in England,
the NIHR RDS may take on this role and advise on
elements of trial design. Furthermore, across the
United Kingdom and Ireland, the establishment of
the MRC Hubs has altered the clinical trial landscape
and are an additional grouping of trial expertise.
Conclusion
The awareness, use, and views of trialists regarding
methods for specifying the target difference varied
both in the United Kingdom and Ireland, and also
internationally. Variations in practice exist, and a
key requirement highlighted was the need for gui-
dance documentation to inform the process. There
would also appear to be a need for more transparent
reporting of the considerations taken into account
when determining the target difference.
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